Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

288383-20-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

288383-20-0 Usage


Cediranib, also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, which play a central role in vasculogenesis and angiogenesis. It is a small molecule drug that targets multiple receptor and non-receptor tyrosine kinases, including those in the platelet-derived growth factor, fibroblast growth factor, and endothelial growth factor receptor families. Cediranib effectively blocks tubule formation by human umbilical vein endothelial cells in vitro and prevents angiogenesis and xenograft tumor growth in vivo. Due to its ability to inhibit angiogenesis, Cediranib has potential use in a range of cancers.


Used in Oncology:
Cediranib is used as an anti-cancer agent for blocking angiogenesis, which is a critical process for tumor growth and progression. It has shown potential in the treatment of various cancers, including cervical cancer, by inhibiting VEGF-stimulated proliferation and KDR phosphorylation with IC50 values of 0.4 and 0.5 nM, respectively.
Used in Molecular Targeted Drug Research:
Cediranib is used as a molecular targeted drug in the study of cervical cancer, where it has shown promise in understanding tumor biology and the development of personalized treatment strategies.
Used in Clinical Applications:
Cediranib is used in clinical applications to evaluate its efficacy and safety in cancer treatment. The drug's ability to inhibit a variety of receptor and non-receptor tyrosine kinases makes it a valuable candidate for further research and development in oncology.
Used in Biomarker Research:
Cediranib is used in the study of correlative biomarkers to better understand tumor biology and predict treatment response. This research can help identify patients who are more likely to benefit from Cediranib treatment and improve the overall effectiveness of cancer therapy.

Anticancer drugs

Cediranib is an oral anticancer drug , it is successfully developed by the US AstraZeneca company , its trade name is recentin, this product is an efficient VEGFR tyrosine kinase inhibitor, it is capable of inhibiting all known VEGFR tyrosine kinases ( including VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR). Cediranib can inhibit VEGF-induced angiogenesis, neovascularization survival and human tumor xenograft cell growth.Clinical trail phase I for non-small cell lung cancer (abbreviated NSCLC) patients shows that cediranib in combination with PC programs has a significant antitumor effect . Clinical trail phaseⅡ/Ⅲ BR24 focuses on using cediranib 30mg as a first-line treatment of NSCLC ,which demonstrates that it has anti-tumor effect, but it has a higher incidence of adverse events, including diarrhea, dehydration, hand-foot syndrome, hypertension and neutropenia disease. Therefore, there is the decision to stop clinical trials. Repeated assessments about toxicity and dose of the combination of drugs suggest that part of the adverse effects are dose-related , dose reduction may be tried to improve drug tolerance. In view of this conclusion, in 2009, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) launched a cediranib clinical trail phase Ⅲ (BR29) for progressive NSCLC patients , the dose was adjusted to 20mg. The results have not been reported. In 2009 ,European Society for Medical Oncology (ESMO) Annual report which is about cediranib treatment of metastatic renal cell carcinoma (referred mRCC) clinical trail phase II shows that cediranib treatment group tumor volume reducing rate is higher than the placebo group. Zurita tested Cediranib pretreatment serum cytokines and angiogenic factors ,and found that patients having low IL-10, VEGF, PIGF, SCF and MIG concentration during baseline time , have the more obvious tumor volume reduction after treatment. The above information is edited by the lookchem of Tian Ye.


[1] wedge sr, kendrew j, hennequin lf, valentine pj, barry st, brave sr, smith nr, james nh, dukes m, curwen jo, chester r, jackson ja, boffey sj, kilburn ll, barnett s, richmond gh, wadsworth pf, walker m, bigley al, taylor st, cooper l, beck s, jürgensmeier jm, ogilvie dj. azd2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. cancer res. 2005 may 15;65(10):4389-400.

Check Digit Verification of cas no

The CAS Registry Mumber 288383-20-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,8,3,8 and 3 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 288383-20:
180 % 10 = 0
So 288383-20-0 is a valid CAS Registry Number.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017


1.1 GHS Product identifier

Product name Cediranib

1.2 Other means of identification

Product number -
Other names 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:288383-20-0 SDS

288383-20-0Downstream Products

288383-20-0Relevant articles and documents

Understanding the Alkylation of a Phenol by 1-(3-Chloropropyl)pyrrolidine: Evidence for the Intermediacy of an Azetidinium Ion

Ashworth, Ian W.,Chan, Lai C.,Cox, Brian G.,McFarlane, Ian M.,Phillips, Andrew R.

, p. 4754 - 4762 (2018/11/25)

The final synthetic step in the synthesis of cediranib, AZD2171, 1, is the alkylation of a phenol with an alkyl halide to generate an ether. Our need to understand and control the formation of synthetic impurities generated in this step of the synthesis led us to investigate the kinetics and mechanism of the alkylation of indolphenol, 2, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinazolin-7-ol, by chloropyrrolidine, 3, 1-(3-chloropropyl)pyrrolidine. Studies in 1-methyl-2-pyrrolidinone (NMP) established that the active alkylating agent is the azetidinium ion, 4, 4-azoniaspiro[3.4]octane, formed via a slow intramolecular cyclization reaction of chloropyrrolidine, 3. The azetidinium ion was isolated as its tetraphenylborate salt from water by heating 3 in the presence of aqueous potassium tetraphenyl borate, and its competence as an intermediate was demonstrated by its fast reaction with 2 to yield cediranib, 1.

Preparation methods for drug cediranib treating non-small cell lung cancer and kidney cancer and intermediate thereof


, (2018/06/15)

The invention discloses preparation methods for a drug cediranib treating non-small cell lung cancer and kidney cancer and an intermediate thereof. The chemical name of the drug cediranib treating non-small cell lung cancer and kidney cancer is 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline, and the structural formula thereof is as shown in the description.The preparation methods are simple, the cediranib intermediate and 5-hydroxy-4-fluoro-2-methylindole are synthesized to obtain cediranib through a condensation reaction, so that the atom is more economical, the reaction is more selective, and the operation is more controllable, the preparation method for the cediranib is more controllable, the product quality is improved, and the economic technology of active ingredients is advanced.



Paragraph 0076; 0077;0078, (2017/03/14)

The present disclosure relates to solid state forms of Cediranib maleate, processes for preparation thereof and pharmaceutical compositions thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 288383-20-0